Department of Urology, Renji Hospital, Shanghai Jiaotong University, Shanghai 200001, China.
Eur J Surg Oncol. 2013 Jan;39(1):100-6. doi: 10.1016/j.ejso.2012.10.004. Epub 2012 Oct 24.
This study was carried out to examine P53-induced Ring-h2 protein (Pirh2) expression and investigate its clinical and prognostic significance in patients with clear cell renal cell carcinoma (ccRCC).
Pirh2 mRNA and protein expressions were detected by quantitative reverse-transcription polymerase chain reaction (Q-RT PCR) and Western blotting in 35 frozen renal cancer tissue specimens and 35 adjacent normal renal tissue specimens of the same patients. Pirh2 protein expression was assessed by immunohistochemical analysis in 92 paraffin-embedded specimens of human ccRCC and 30 specimens of adjacent normal renal tissue. Correlations between Pirh2 and clinicopathologic features and prognosis were analyzed statistically.
Pirh2 mRNA and protein levels in ccRCC samples were increased significantly as compared with the adjacent normal renal tissues (P < 0.001). Pirh2 mRNA overexpression correlated with high stage and grade of the renal cancer (P < 0.001 and P < 0.001 respectively). Pirh2 protein expression was negative in most normal renal tissue specimens (23/30) but positive in 52.2% (48/92) of ccRCC specimens (P = 0.006). Pirh2 protein expression correlated with tumor grade and stage (P < 0.001 and P < 0.001 respectively). The median follow-up interval was 42.0 months. Overexpression of Pirh2 protein in ccRCC was significantly associated with shorter overall survival and recurrence-free survival (P = 0.001 and P = 0.003, respectively). Multivariate analysis showed that Pirh2 expression was an independent prognostic factor for ccRCC patients (P = 0.037).
Pirh2 was up-regulated in ccRCC at both transcriptional and translational levels compared with normal renal tissues, suggesting that Pirh2 may be a potential prognostic marker for ccRCC.
本研究旨在检测 P53 诱导的环指蛋白 2(Pirh2)表达,并探讨其在透明细胞肾细胞癌(ccRCC)患者中的临床及预后意义。
采用定量逆转录聚合酶链反应(Q-RT-PCR)和 Western blot 检测 35 例冷冻肾癌组织标本和同期 35 例配对正常肾组织标本中 Pirh2 mRNA 和蛋白的表达,采用免疫组织化学分析 92 例人 ccRCC 石蜡包埋标本和 30 例配对正常肾组织标本中 Pirh2 蛋白的表达,统计分析 Pirh2 与临床病理特征及预后的相关性。
与配对正常肾组织相比,ccRCC 组织中 Pirh2 mRNA 和蛋白水平显著升高(P<0.001)。Pirh2 mRNA 过表达与肾癌的高分期和高分级相关(P<0.001 和 P<0.001)。30 例配对正常肾组织中,大多数正常肾组织标本(23/30)中 Pirh2 蛋白表达阴性,而 92 例 ccRCC 标本中 52.2%(48/92)呈阳性(P=0.006)。Pirh2 蛋白表达与肿瘤分级和分期相关(P<0.001 和 P<0.001)。中位随访时间为 42.0 个月。ccRCC 中 Pirh2 蛋白的过表达与总生存期和无复发生存期较短显著相关(P=0.001 和 P=0.003)。多因素分析显示,Pirh2 表达是 ccRCC 患者的独立预后因素(P=0.037)。
与正常肾组织相比,ccRCC 在转录和翻译水平均上调 Pirh2 的表达,提示 Pirh2 可能是 ccRCC 的潜在预后标志物。